Aarti Drugs to hold virtual investor meeting on June 10

1 min read Updated on 05 Jun 2026, 01:15 PM

Reviewed by

Ashish TScanX News Team

AI Summary

Aarti Drugs Limited will conduct a virtual analyst and institutional investor meeting on June 10, 2026, organized by Choice Institutional Equities. The company confirmed that no unpublished price sensitive information will be discussed. The disclosure was made in compliance with Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

*this image is generated using AI for illustrative purposes only.

Aarti Drugs Limited has scheduled a virtual meeting with analysts and institutional investors for June 10, 2026. The session will take place between 12:00 PM and 1:00 PM and is organized by Choice Institutional Equities. The company stated that discussions will be based solely on publicly available information and no unpublished price sensitive information (UPSI) will be shared.

The meeting is being held pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates the disclosure of such investor interactions to ensure transparency.

The following table outlines the details of the scheduled meeting:

Date & Time	Nature of Meeting	Organised by	Venue
10 June 2026 12:00 PM to 1:00 PM	Group Meeting	Choice Institutional Equities	Virtual

Rushikesh Deole, Company Secretary & Compliance Officer of Aarti Drugs Limited, signed the intimation submitted to the stock exchanges on June 05, 2026. The company noted that changes to the schedule may occur due to exigencies on the part of the host or the company.

Aarti Drugs Limited is a manufacturer of bulk drugs and chemicals, headquartered in Mumbai. The intimation was addressed to the Listing and Compliance Departments of both BSE Limited and the National Stock Exchange of India Limited.

Historical Stock Returns for Aarti Drugs

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.53%	-3.59%	-4.80%	-7.60%	-20.44%	-50.39%

What key strategic priorities is Aarti Drugs likely to emphasize during the meeting to attract institutional investors?

How might the company address recent industry challenges, such as regulatory changes or supply chain disruptions, in the discussion?

What impact could this investor meeting have on Aarti Drugs' stock performance in the short term?

Read Next Article

Aarti Drugs Q4 PAT Rises 36% QoQ to INR55.3 Crores

1 min read Updated on 25 May 2026, 06:11 PM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

AI Summary

Aarti Drugs reported a 6% YoY increase in Q4 FY26 revenue to INR721.1 crores, driven by a 41% YoY rise in formulation revenue. While PAT declined 12% YoY to INR55.3 crores, it improved 36% sequentially. EBITDA for the quarter stood at INR96.6 crores with a 13.4% margin. The company is ramping up its methylamines plant, targeting 70% utilization within a year. For FY27, management projects EBITDA margins between 13.5% and 14% and has outlined a capex plan of INR300-400 crores over the next few years.

*this image is generated using AI for illustrative purposes only.

Aarti Drugs Limited has reported its financial results for the quarter and year ended March 31, 2026. The company posted a revenue of INR721.1 crores for Q4 FY26, reflecting a growth of 6% year-on-year and 20% quarter-on-quarter. EBITDA stood at INR96.6 crores, an increase of 72% quarter-on-quarter, with a margin of 13.4%. Profit after tax (PAT) for the quarter was INR55.3 crores, a decline of 12% year-on-year but an increase of 36% quarter-on-quarter.

Financial Performance

The standalone business contributed 88% to the consolidated revenue, recording INR631.7 crores. Domestic revenue grew by 7% year-on-year, while export revenue declined by 7% year-on-year. The formulation segment showed strong performance, with revenue rising 41% year-on-year to INR91.3 crores. For the full fiscal year FY26, formulation revenue reached INR330.5 crores, up 16% from the previous year.

Metric	Q4 FY26	Q4 FY25	Q3 FY26
Revenue (INR Crores)	721.1	678.6	602.9
EBITDA (INR Crores)	96.6	95.2	56.3
PAT (INR Crores)	55.3	62.8	40.5

Operational Highlights

The company noted that FY26 was a transition year marked by the scale-up of new manufacturing facilities. The backward integration plant for methylamines at Sayakha achieved a production rate of nearly 1,000 tonnes per month in March 2026. Management expects utilization to cross 55-60% in the June quarter and reach upwards of 70% within a year. The facility is expected to reduce dependence on external inputs and improve margins for the metformin portfolio.

Outlook

Looking ahead to FY27, the company targets EBITDA margins between 13.5% and 14%, contingent on geopolitical factors and crude oil prices. The management indicated a capex plan of INR300 crores to INR400 crores over the next two to three years, focusing on brownfield expansions and formulation capacity. The company has filed a DMF for metformin with the US FDA and plans to invite inspectors for its dedicated facility.

Historical Stock Returns for Aarti Drugs

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.53%	-3.59%	-4.80%	-7.60%	-20.44%	-50.39%

How might Aarti Drugs' US FDA DMF filing for metformin translate into export revenue recovery, and what timeline could investors expect for meaningful US market contributions?

Given the 7% year-on-year decline in export revenue, which geographies or product segments pose the greatest risk to Aarti Drugs' ability to achieve its FY27 EBITDA margin targets of 13.5-14%?

As the methylamines backward integration plant scales toward 70% utilization, how significantly could the resulting cost savings reshape Aarti Drugs' competitive positioning against Chinese API manufacturers?